Dexak
Poland
Table of Contents
Patient Information Leaflet
Warning! Keep this leaflet. Information on the immediate packaging is in a foreign language.
Dexak (Ketesse)
25 mg, coated tablets
Dexketoprofen
Dexak and Ketesse are different brand names for the same medicine.
Please read this leaflet carefully before taking the medicine, as it contains
important information for the patient.
- Always take this medicine exactly as described in this patient leaflet or as directed by your doctor or pharmacist.
- Keep this leaflet, as you may need to read it again.
- If you need advice or further information, consult your pharmacist.
- If you experience any adverse reactions, including any possible side effects not listed in this leaflet, inform your doctor, pharmacist, or nurse. See section 4.
- If there is no improvement or if your condition worsens after 3–4 days, contact your doctor.
Table of contents:
- What Dexak is and what it is used for
- Important information before taking Dexak
- How to take Dexak
- Possible side effects
- How to store Dexak
- Contents of the pack and other information
1. What Dexak is and what it is used for
Dexak is an analgesic medicine belonging to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
It is used for symptomatic treatment of mild to moderate pain, such as muscle pain, painful menstruation (dysmenorrhoea), or toothache.
If there is no improvement or if you feel worse after 3–4 days, consult your doctor.
2. Information before using Dexak
When not to use Dexak:
- If the patient is allergic to dexketoprofen or any of the other ingredients of this medicine (listed in section 6);
- If the patient is allergic to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs);
- If the patient has asthma or has previously experienced asthma attacks, acute allergic rhinitis (a short period of inflammation of the nasal lining), nasal polyps (nasal growths caused by allergy), urticaria (blistering rash), angioedema (swelling of the face, eyes, lips, tongue or a combination of breathing difficulties), or wheezing after taking acetylsalicylic acid or another NSAID;
- If the patient has previously experienced photosensitivity reactions: photoallergic or phototoxic reactions (particularly redness and/or blisters on skin exposed to sunlight) while taking ketoprofen (a non-steroidal anti-inflammatory drug) or fibrates (medicines used to lower blood lipid levels);
- If the patient has gastric or duodenal ulcer disease and/or bleeding from the stomach or intestines, or if there has been previous gastrointestinal bleeding, ulceration, or perforation;
- If the patient has chronic digestive problems (e.g. indigestion, heartburn);
- If the patient has previously experienced gastrointestinal bleeding or perforation due to prior use of NSAIDs used to treat pain;
- If the patient has intestinal diseases with chronic inflammation (Crohn's disease or ulcerative colitis);
- If the patient has severe heart failure, moderate or severe renal failure, or severe hepatic impairment;
- If the patient has a tendency to bleed excessively or has coagulation disorders;
- If the patient is severely dehydrated (excessive loss of body fluids) due to vomiting, diarrhoea, or inadequate fluid intake;
- If the patient is in the third trimester of pregnancy or is breastfeeding.
Warnings and precautions
Before starting Dexak, discuss with a doctor or pharmacist:
- If the patient has allergies or has previously experienced allergy-related problems;
- If the patient has kidney, liver, or heart dysfunction (hypertension and/or heart failure), fluid retention, or if any of these conditions occurred in the past;
- In patients receiving diuretics or in patients with reduced hydration and blood volume due to excessive fluid loss (e.g. frequent urination, diarrhoea, or vomiting);
- If the patient has heart problems, has had a stroke, or is suspected of being at risk for these conditions (e.g. due to high blood pressure, diabetes, high cholesterol levels, or smoking). In such cases, consult a doctor before using Dexak. Use of medicines such as Dexak may be associated with a small increased risk of heart attack ("myocardial infarction") or stroke. This risk increases with long-term use of high doses. Do not use higher doses or longer treatment duration than recommended;
- If the patient is elderly: there is an increased risk of adverse effects (see section 4). In such cases, contact a doctor immediately;
- In women experiencing fertility problems or undergoing fertility testing (this medicine may impair female fertility and is not recommended for women planning pregnancy or undergoing infertility treatment);
- If the patient has blood or blood cell formation disorders;
- If the patient has systemic lupus erythematosus or mixed connective tissue disease (immune system disorders affecting connective tissue);
- If the patient has previously had chronic inflammatory bowel diseases (ulcerative colitis, Crohn's disease);
- If the patient has or has had other stomach or intestinal disorders;
- If the patient has an infection – see below, section titled "Infections";
- If the patient is taking other medicines that increase the risk of gastric or duodenal ulceration or bleeding, e.g. oral corticosteroids, certain antidepressants (SSRI group drugs, e.g. serotonin reuptake inhibitors), anticoagulants such as acetylsalicylic acid, or anticoagulant drugs such as warfarin. In such cases, consult a doctor before taking this medicine, who may
decide to prescribe an additional protective medicine (e.g. misoprostol or
medicines that inhibit gastric acid production);
- If the patient has asthma, chronic rhinitis, chronic sinusitis, and/or nasal polyps, the risk of allergy to acetylsalicylic acid and/or NSAIDs is higher than in the general population. Taking this medicine may trigger asthma attacks or bronchospasm, especially in patients allergic to acetylsalicylic acid and/or NSAIDs.
Infections
Dexketoprofen may mask symptoms of infection such as fever and pain. Therefore, this medicine may
delay appropriate treatment of infection and consequently increase the risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections associated with chickenpox. If the patient takes this medicine during an infection and symptoms persist or worsen, consult a doctor immediately.
Avoid using this medicine during chickenpox.
Children and adolescents
The use of this medicine has not been studied in children and adolescents. The safety and efficacy have not been established, and therefore this medicine should not be used in children and adolescents.
Dexak with other medicines
Inform the doctor about all medicines currently taken, recently taken, or planned to be taken. Some medicines should not be used together with Dexak, and for others, dosage adjustment may be necessary when used concomitantly with Dexak.
Always inform the doctor, dentist, or pharmacist if taking any of the following medicines together with this medicine:
- Not recommended for concomitant use:
- Acetylsalicylic acid, corticosteroids, or other anti-inflammatory medicines
- Warfarin, heparin, or other anticoagulant medicines
- Lithium used to treat certain mood disorders
- Methotrexate (an anticancer or immunosuppressive medicine) used in high doses of 15 mg per week
- Hydantoin derivatives and phenytoin used to treat epilepsy
- Sulfamethoxazole used to treat bacterial infections.
- Concomitant use requiring caution:
- ACE inhibitors, diuretics, and angiotensin II antagonists used to treat high blood pressure and heart disease
- Pentoxifylline and oxpentifylline used to treat ulcers in chronic venous insufficiency
- Zidovudine used to treat viral infections
- Aminoglycoside antibiotics used to treat bacterial infections
- Sulfonylurea derivatives (e.g. chlorpropamide and glibenclamide) used to treat diabetes
- Methotrexate used in low doses, below 15 mg per week
- Concomitant use requiring special consideration:
- Quinolone antibiotics (e.g. ciprofloxacin, levofloxacin) used to treat bacterial infections
- Cyclosporine and tacrolimus used to treat immune system disorders and in transplant patients
- Streptokinase and other thrombolytic or fibrinolytic medicines, i.e. medicines used to dissolve blood clots
- Probenecid used to treat gout
- Digoxin used to treat chronic heart failure
- Mifepristone used as an abortion-inducing agent (terminates pregnancy)
- Selective serotonin reuptake inhibitors (SSRI) antidepressants
- Antiplatelet medicines used to reduce platelet aggregation and blood clot formation
- Beta-adrenergic blocking agents (beta-blockers) used to treat high blood pressure and heart disease
- Tenofovir, deferasirox, pemetrexed.
If in doubt about the use of Dexak, consult a doctor or pharmacist.
Taking Dexak with food and drink
Dexak tablets should be swallowed with sufficient water. Taking the tablets with food may reduce the risk of gastrointestinal side effects. However, in case of acute pain, it is recommended to take the medicine on an empty stomach, e.g. at least 30 minutes before a meal, to allow faster onset of action.
Pregnancy, breastfeeding, and effect on fertility
If the patient is pregnant, breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult a doctor or pharmacist before using this medicine.
Do not take this medicine if the patient is in the last three months of pregnancy or during breastfeeding. It may cause kidney and heart problems in the unborn child. It may increase the tendency to bleeding in both mother and child and may delay or prolong labour.
During the first six months of pregnancy, this medicine should not be used unless the doctor considers it absolutely necessary. If treatment is required during this period or when trying to conceive, the lowest possible dose should be used for the shortest possible time.
From week 20 of pregnancy, Dexak, if taken for longer than a few days, may cause:
renal function disorders in the unborn child – this may lead to reduced amniotic fluid volume surrounding the child (oligohydramnios) or constriction of blood vessels (ductus arteriosus) in the child's heart. If treatment for longer than a few days is necessary, the doctor may recommend additional monitoring.
This medicine is not recommended for women planning pregnancy or undergoing fertility testing.
Information on potential effects on fertility is provided in section 2, "Warnings and precautions".
Driving and operating machinery
This medicine may cause dizziness and fatigue and therefore may have a minor or moderate effect on the ability to drive motor vehicles and operate machinery. If such symptoms occur, do not drive motor vehicles or operate mechanical equipment until symptoms resolve. If in doubt, consult a doctor.
Dexak contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, meaning the medicine is considered "sodium-free".
3. How to use Dexak
This medicine should always be taken exactly as described in the patient leaflet or as directed by a doctor or pharmacist. If in doubt, consult a doctor or pharmacist.
Use the lowest effective dose for the shortest duration necessary to relieve symptoms. If symptoms of infection (such as fever and pain) persist or worsen, consult a doctor immediately (see section 2).
Tablets may be divided into equal doses by breaking them along the score line.
The usual recommended daily dose is half a tablet (12.5 mg) every 4 to 6 hours or one tablet (25 mg) every 8 hours, but not more than 3 tablets per day (75 mg).
If there is no improvement after 3 to 4 days, or if the patient feels worse, contact a doctor. The doctor will inform the patient how many tablets to take per day and for how long.
The dose of this medicine will depend on the type, severity, and duration of the patient's pain.
For elderly patients or those with kidney or liver disease, it is recommended to start treatment with a lower total daily dose corresponding to no more than 2 coated tablets (50 mg).
In elderly patients who tolerate the initial dose well, the dose may subsequently be increased to the recommended dose for the general population (75 mg).
For acute pain requiring faster relief, it is recommended to take the medicine on an empty stomach (at least 30 minutes before a meal), which will result in faster absorption of the medicine (see section 2 "Taking this medicine with food and drink").
Use in children and adolescents
This medicine must not be used in children and adolescents under 18 years of age.
Taking more Dexak than recommended
If an overdose is suspected, inform a doctor or pharmacist immediately or go to the nearest hospital emergency department. Remember to bring the medicine packaging or patient leaflet with you.
Missed dose of Dexak
Do not take a double dose to make up for a missed dose. The next dose should be taken according to the prescribed dosing schedule (see section 3 "How to use Dexak").
If there are any further questions about the use of this medicine, consult a doctor or pharmacist.
4. Possible adverse effects
Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.
The possible adverse effects are listed below, categorized according to their likelihood of occurrence.
Common adverse effects (may affect up to 1 in 10 people):
Nausea and/or vomiting, abdominal pain, mainly in the upper quadrants, diarrhoea, indigestion (dyspepsia).
Uncommon adverse effects (may affect up to 1 in 100 people):
Vertigo (vestibular origin), drowsiness, sleep disturbances, nervousness, headache, palpitations, facial flushing, inflammation of the gastric mucosa (gastritis), constipation, dryness of the oral mucosa, flatulence, rash, fatigue, pain, feeling of fever and chills, malaise.
Rare adverse effects (may affect up to 1 in 1000 people):
Peptic ulcer disease, gastrointestinal bleeding or perforation (which may present as bloody vomit or black stools), fainting, hypertension, reduced respiratory rate, fluid retention in the extremities and peripheral oedema (e.g. swollen ankles), throat swelling, loss of appetite (anorexia), abnormal sensations, itchy rash, acne, increased sweating, back pain, increased urination, menstrual disorders, prostate gland disorders, abnormal liver function tests (blood tests), liver cell damage (hepatitis), acute kidney failure.
Very rare adverse effects (may affect up to 1 in 10,000 people):
Anaphylactic reactions (acute hypersensitivity reactions which may lead to anaphylactic shock), skin, lip, eye and genital ulceration (Stevens-Johnson syndrome and Lyell's syndrome), facial swelling or swelling of lips and throat (angioedema), shortness of breath due to bronchial muscle spasm (bronchospasm), shortness of breath, rapid heartbeat, low blood pressure, pancreatitis, blurred vision, tinnitus, skin hypersensitivity reactions and photosensitivity, itching, kidney damage, reduced white blood cell count (neutropenia), reduced platelet count (thrombocytopenia).
Patients should inform their doctor if they experience any adverse effects affecting the stomach or intestines at the beginning of treatment (e.g. stomach pain, heartburn or bleeding), especially if they have previously experienced similar adverse effects due to long-term use of anti-inflammatory medicines, particularly elderly patients.
If a skin rash, any mucosal lesion (e.g. inside the mouth), or any allergic symptoms occur, treatment with this medicine should be stopped immediately.
During administration of non-steroidal anti-inflammatory drugs (NSAIDs), fluid retention and oedema (particularly in ankles and legs), increased blood pressure and heart failure may occur.
Use of medicines such as this one may be associated with a small increased risk of heart attack ("myocardial infarction") or cerebrovascular events (stroke).
In patients with systemic lupus erythematosus or mixed connective tissue disease (immunological connective tissue disorders), administration of anti-inflammatory medicines may rarely cause fever, headache and neck stiffness.
The most frequently observed adverse effects involved gastrointestinal disturbances. Particularly in elderly patients, gastric ulcer disease, perforation or bleeding from the stomach and/or duodenum may occur, in some cases with fatal outcome.
After administration of the medicine, the following have been observed: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, lower abdominal pain, tarry stools, bloody vomit, ulcerative inflammation of the oral mucosa, exacerbation of colitis and Crohn's disease. Gastritis has been observed less frequently.
As with other NSAIDs, haematological reactions may occur (purpura, aplastic and haemolytic anaemia, rarely agranulocytosis and bone marrow hypoplasia).
Reporting of adverse effects
If any adverse effects occur, including any not listed in this leaflet, patients should inform their doctor, pharmacist or nurse.
Adverse effects can be reported directly to the Department of Monitoring Adverse Effects of Medicinal Products, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Tel.: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Reporting adverse effects helps to provide more information on the safety of the medicine.
5. How to store Dexak
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
Do not store above 30°C. Store in the original packaging to protect from light.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Contents of the packaging and other information
What Dexak contains
- The active substance is dexketoprofen (in the form of dexketoprofen trometamol). Each coated tablet contains 25 mg of dexketoprofen.
- Other ingredients are: Tablet core: maize starch, microcrystalline cellulose, sodium carboxymethyl starch, glycerol distearate. Coating: dry coat (composition: hypromellose, titanium dioxide, polyethylene glycol 6000), propylene glycol.
What Dexak looks like and contents of the pack
White, round, biconvex coated tablets with a dividing score line, in blisters.
The medicine is available in packs containing 10, 20 or 30 coated tablets.
For more detailed information, please contact the marketing authorisation holder
or the parallel importer.
Marketing Authorisation Holder in Spain, the country of export:
Menarini International O.L., S.A.
1, Avenue de la Gare, L-1611 Luxembourg
Luxembourg
Manufacturer:
Laboratorios Menarini, S.A.
Alfons XII, 587 - Badalona (Barcelona)
Spain
Parallel Importer:
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Repackaged by:
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Marketing authorisation number in Spain, the country of export: 681924.1
Parallel import authorisation number: 330/25
This medicine is authorised for sale in the European Economic Area and the United Kingdom (Northern Ireland) under the following names:
Spain (RMS), Austria, Belgium, Finland, France, Italy, Luxembourg, Portugal: Ketesse
Cyprus, Greece: Nosatel
Czech Republic: Dexoket
Germany: Sympal
Estonia, Latvia, Lithuania: Dolmen
Hungary: Ketodex
Ireland, Malta, United Kingdom (Northern Ireland): Keral
Netherlands: Stadium
Poland: Dexak
Slovakia: Dexadol
Slovenia: Menadex